Greenfield-based Elanco Animal Health was the first to market two years ago with the only treatment for canine parvovirus.
Now, there is even more protection for pups. Elanco recently earned clearance from the U.S. Department of Agriculture to give the medication to also prevent the virus.
The virus infects puppies that aren’t yet fully vaccinated and can cause vomiting and diarrhea that is usually deadly, killing up to 91% of dogs if they’re not treated.
“In the shelter space, parvovirus can be so deadly and devastating, because if you think about the population of shelter, you’ve got all these puppies coming in. You don’t know their backgrounds. You don’t know if they’ve been vaccinated,” said Dr. Jennifer Miller, a veterinarian who is leading Elanco’s medical strategy.
Miller calls the medication, known as the canine parvovirus monoclonal antibody, or CPMA, a game changer and “a revolutionary product for veterinary medicine.”
She said while there is a vaccine for parvovirus that works really well, the difficulty is that puppies are in the highest risk group before they event start receiving vaccines.
“The younger the puppy, the higher the risk group they are [in] for getting parvo infection, and often these puppies that get infected, they either haven’t had any vaccines yet or they’re not completely through their vaccine series yet,” she said.
Miller said the CPMA medication stops the virus dead in its tracks, giving puppies a better fighting chance for recovery. Now that it is approved as a preventative measure, puppies have an even greater chance of survival.
“We give it to that puppy before they even get exposed to parvovirus, and then it’s already there; it’s circulating,” she said. “So if they get that exposure, or when they get that exposure, it’s ready to fight from day zero.”
Miller noted that they have seen a big improvement in real-world cases on how the treatment is impacting the operations of animal clinics.
“Getting CPMA on board for these puppies in their treatment protocols has decreased the amount of time that these puppies have to go into the hospital,” she said. “What we’re seeing showing up in real-world results is 1.87 less days of hospital time for these puppies to be in the parvo ICU.”
Elanco is only the second animal health company in the United States to produce a monoclonal antibody, which Miller said has been a new experience for the company. She says now, they are working to get the word out to shelters and veterinarians about the treatment.
The company is also seeking to educate dog owners about the signs and symptoms of parvovirus, so they can get treatment as quickly as possible.
Elanco says it has donated more than $3 million worth of the medicine to shelters and clinics throughout the country, including Indiana.
The development of this drug stems from Elanco’s purchase of California-based Kindred Biosciences Inc., which was developing the treatment. The company acquired Kindred in August 2021 in a deal valued at approximately $440 million.
